Split History
IDRA split history picture
Idera Pharmaceuticals (IDRA) has 1 split in our IDRA split history database. The split for IDRA took place on July 30, 2018. This was a 1 for 8 reverse split, meaning for each 8 shares of IDRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.

When a company such as Idera Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.

Looking at the IDRA split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Idera Pharmaceuticals shares, starting with a $10,000 purchase of IDRA, presented on a split-history-adjusted basis factoring in the complete IDRA split history. IDRA split adjusted history picture

Growth of $10,000.00
Without Dividends Reinvested

Start date: 10/01/2012
End date: 09/27/2022
Start price/share: $8.16
End price/share: $0.37
Dividends collected/share: $0.00
Total return: -95.47%
Average Annual Total Return: -26.62%
Starting investment: $10,000.00
Ending investment: $453.43
Years: 9.99
Idera Pharmaceuticals is a biopharmaceutical company focused on the clinical development, and the commercialization, of drug candidates for rare disease indications characterized by patient populations with unmet medical needs. Co.'s focus is to identify and acquire rights to development and commercial stage rare disease programs through new business development opportunities, including additional alternatives. Co. is evaluating intratumoral tilsotolimod in combination with nivolumab, an anti-Progressive Disease 1 antibody marketed as Opdivo® by Bristol Myers Squibb Company, and ipilimumab for the treatment of multiple solid tumors in a multicohort trial. According to our IDRA split history records, Idera Pharmaceuticals has had 1 split.
Date Ratio
07/30/20181 for 8
IDRA is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:

IDXG Split History
IDXX Split History
IGC Split History
IIN Split History
ILMN Split History
IMMY Split History
IMNP Split History
IMPL Split History
IMRS Split History
IMUC Split History

Also explore: IDRA shares outstanding history

Email EnvelopeFree IDRA Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Avenue Therapeutics, Inc. (ATXI)
Annaly Capital Management, Inc. (NLY)
CohBar, Inc. (CWBR)
TOP Ships Inc. (TOPS)
Sonnet BioTherapeutics Holdings, Inc. (SONN)
Nabriva Therapeutics plc (NBRV)
NeuroBo Pharmaceuticals, Inc. (NRBO)
First Wave BioPharma, Inc. (FWBI)
Palatin Technologies, Inc. (PTIN)
TD Holdings, Inc. (GLG )
More latest stock splits »
Latest mega mergers »
Latest stock buybacks »

IDRA Insider Buying

IDRA Split History | www.SplitHistory.com | Copyright © 2013 - 2022, All Rights Reserved

Nothing in www.SplitHistory.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.